

- ketoconazole and fluconazole, upon steroidogenesis in rat adrenal cells in vitro [J]. J Steroid Biochem, 1988, 31 (5): 819-823. DOI:10.1016/0022-4731(88)90291-9.
- [6] Riedl M, Maier C, Zettinig G, et al. Long term control of hypercortisolism with fluconazole; case report and in vitro studies [J]. Eur J Endocrinol, 2006, 154 (4): 519-524. DOI: 10.1530/eje.1.02120.
- [7] Van Der Pas R, Hofland LJ, Hofland J, et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro [J]. J Endocrinol, 2012, 215 (3): 403-412. DOI:10.1530/JOE-12-0310.
- [8] Zhao Y, Liang W, Cai F, et al. Fluconazole for hypercortisolism in Cushing's disease: a case report and literature review [J]. Front Endocrinol (Lausanne), 2020, 11: 608886. DOI: 10.3389/fendo.2020.608886.
- [9] Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy [J]. N Engl J Med, 1994, 330 (4): 1759-1760. DOI:10.1056/NEJM199406163302416.
- [10] Alexandraki KI, Grossman AB. Therapeutic strategies for the treatment of severe Cushing's syndrome [J]. Drugs, 2016, 76 (4): 447-458. DOI:10.1007/s40265-016-0539-6.
- [11] Burns K, Christie-David D, Gunton JE. Fluconazole in the treatment of Cushing's disease [J]. Endocrinol Diabetes Metab Case Rep, 2016, 2016: 150115. DOI:10.1530/EDM-15-0115.
- [12] Schwetz V, Aberer F, Stiegler C, et al. Fluconazole and acetazolamide in the treatment of ectopic Cushing's syndrome with severe metabolic alkalosis [J]. Endocrinol Diabetes Metab Case Rep, 2015, 2015: 150027. DOI:10.1530/EDM-15-0027.
- [13] Canteros TM, De Miguel V, Fainstein-Day P. Fluconazole treatment in severe ectopic Cushing syndrome [J]. Endocrinol Diabetes Metab Case Rep, 2019, 2019 (1): 0019-0020. DOI: 10.1530/EDM-19-0020.
- [14] Davis MR, Nguyen MH, Donnelley MA, et al. Tolerability of long-term fluconazole therapy [J]. J Antimicrob Chemother, 2019, 74 (3): 768-771. DOI:10.1093/jac/dky501.
- [15] Albert SG, DeLeon MJ, Silverberg AB. Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients [J]. Crit Care Med, 2001, 29 (3): 668-670. DOI:10.1097/00003246-200103000-00039.
- [16] Shibata S, Kami M, Kanda Y, et al. Acute adrenal failure associated with fluconazole after administration of high-dose cyclophosphamide [J]. Am J Hematol, 2001, 66 (4): 303-305. DOI:10.1002/ajh.1063.
- [17] Huang YW, Chang CC, Sun HY, et al. Primary adrenal insufficiency in patients with acquired immunodeficiency syndrome; report of four cases [J]. J Microbiol Immunol Infect, 2004, 37 (4): 250-253.
- [18] Santhana Krishnan SG, Cobbs RK. Reversible acute adrenal insufficiency caused by fluconazole in a critically ill patient [J]. Postgrad Med J, 2006, 82 (971): e23. DOI: 10.1136/pgmj.2006.047258.
- [19] Magill SS, Puthanakit T, Swoboda SM, et al. Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients [J]. Antimicrob Agents Chemother, 2004, 48 (7): 2471-2476. DOI: 10.1128/AAC.48.7.2471-2476.2004.
- [20] 杜琴, 赵蓓蓓, 高玉婷, 等. 串联质谱法检测尿皮质醇和唾液皮质醇在库欣综合征诊断中的研究进展 [J]. 国际内分泌代谢杂志, 2020, 40 (1): 39-44. DOI:10.3760/cma.j.issn.1673-4157.2020.01.009.
- [21] Hur KY, Kim JH, Kim BJ, et al. Clinical guidelines for the diagnosis and treatment of Cushing's disease in Korea [J]. Endocrinol Metab (Seoul), 2015, 30 (1): 7-18. DOI:10.3803/EnM.2015.30.1.7.
- [22] Valassi E, Aulinas A, Glad CA, et al. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome [J]. Clin Endocrinol (Oxf), 2017, 87 (5): 433-439. DOI:10.1111/cen.13414.

(收稿日期:2020-06-24)

(本文编辑:王连弟)

· 外刊拾贝 ·

散发性嗜铬细胞瘤患者的术后复发率及推荐随访时间:一项系统评价及荟萃分析

目前关于散发性嗜铬细胞瘤患者的术后复发率及推荐随访时间缺乏证据,包括美国及欧洲的内分泌学会对此含糊不清。Holscher 等为此进行了本研究。他们纳入了在 PubMed、Embase 和 Cochrane 数据库中 13 项研究的 430 例患者,并排除了 1990 年以前的研究、随访 2 年以下的研究、总例数在 10 例以下的研究,以及异质性差的研究。荟萃分

析结果显示,散发性嗜铬细胞瘤的总复发率为 3%,累计平均复发时间为 49.4 个月,平均随访期为 77.3 个月。因此他们的结论是,散发性嗜铬细胞瘤术后复发的概率非常低,在制定随访策略时可据此调整。

[杨菊红,摘译自 Holscher I, van den Berg TJ, Dreijerink KM, et al. Recurrence rate of sporadic pheochromocytomas after curative adrenalectomy: a systematic review and meta-analysis. J Clin Endocrinol Metab, 2021, 106 (2): 588-597.]